Keine Story von Vasogen Inc. mehr verpassen.

Vasogen Inc.

  • 18.01.2008 – 12:08

    The Lancet Publishes Vasogen's ACCLAIM Results

    Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's ...

  • 18.04.2007 – 15:01

    Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union

    Toronto, Canada (ots/PRNewswire) - - Vasogen to Host Conference Call Today at 9:00 a.m. (ET) Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic ...